Business Description
Omeros Corp
NAICS : 325412
SIC : 2834
ISIN : US6821431029
Share Class Description:
STU:3O8: Ordinary SharesDescription
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.73 | |||||
| Equity-to-Asset | -0.07 | |||||
| Debt-to-Equity | -9.47 | |||||
| Debt-to-EBITDA | -1.65 | |||||
| Piotroski F-Score | 5/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 8.1 | |||||
| 3-Year EPS without NRI Growth Rate | -0.5 | |||||
| 3-Year Book Growth Rate | 40.7 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.39 | |||||
| 9-Day RSI | 40.43 | |||||
| 14-Day RSI | 41.2 | |||||
| 6-1 Month Momentum % | 216.85 | |||||
| 12-1 Month Momentum % | -38.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.09 | |||||
| Quick Ratio | 4.09 | |||||
| Cash Ratio | 3.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.3 | |||||
| Shareholder Yield % | 15.04 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -482.07 | |||||
| ROA % | -23.1 | |||||
| ROIC % | -62.67 | |||||
| ROC (Joel Greenblatt) % | -247.59 | |||||
| ROCE % | -37.32 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Price-to-Owner-Earnings | 2.07 | |||||
| Price-to-Free-Cash-Flow | 2.66 | |||||
| Price-to-Operating-Cash-Flow | 2.66 | |||||
| EV-to-EBIT | -1.72 | |||||
| EV-to-Forward-EBIT | -0.6 | |||||
| EV-to-EBITDA | -1.73 | |||||
| EV-to-Forward-EBITDA | -0.6 | |||||
| EV-to-Forward-Revenue | 13.29 | |||||
| EV-to-FCF | 3.31 | |||||
| Earnings Yield (Greenblatt) % | -58.14 | |||||
| FCF Yield % | 40.94 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Omeros Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.749 | ||
| Beta | 2.32 | ||
| Volatility % | 136.98 | ||
| 14-Day RSI | 41.2 | ||
| 14-Day ATR (€) | 0.133295 | ||
| 20-Day SMA (€) | 3.0492 | ||
| 12-1 Month Momentum % | -38.21 | ||
| 52-Week Range (€) | 1.002 - 7 | ||
| Shares Outstanding (Mil) | 57.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Omeros Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Omeros Corp Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Omeros Corp Frequently Asked Questions
What is Omeros Corp(STU:3O8)'s stock price today?
The current price of STU:3O8 is €2.87. The 52 week high of STU:3O8 is €7.00 and 52 week low is €1.00.
When is next earnings date of Omeros Corp(STU:3O8)?
The next earnings date of Omeros Corp(STU:3O8) is 2024-05-09 Est..
Does Omeros Corp(STU:3O8) pay dividends? If so, how much?
Omeros Corp(STU:3O8) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers